Sugi Predict

Sugi Predict / Compounds / SCHEMBL19897449

SCHEMBL19897449

SCHEMBL19897449

O=CCN1CC[C@H](C(=O)O)C1

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ S1PR5 Q9H228 3/20 0.41
▸ S1PR4 O95977 1/20 0.41
▸ S1PR1 P21453 1/20 0.41
▸ S1PR3 Q99500 1/20 0.41
▸ SLC6A11 P48066 1/20 0.40
▸ CYP1A2 P05177 2/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ NOTUM Q6P988 1/20 0.40
▸ SLC6A1 P30531 2/20 0.38
▸ CYP2D6 P10635 1/20 0.38
▸ CYP2C9 P11712 1/20 0.38
▸ TSHR P16473 1/20 0.38
▸ NFKB1 P19838 1/20 0.38
▸ CYP2C19 P33261 1/20 0.38
▸ HSD17B10 Q99714 1/20 0.38
▸ ALDH1A1 P00352 1/20 0.38
▸ LMNA P02545 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7406444 1.00 S1PR5 (0.41) S1PR5S1PR4S1PR1S1PR3SLC6A11
SCHEMBL19897466 1.00 S1PR5 (0.41) S1PR5S1PR4S1PR1S1PR3SLC6A11
SCHEMBL3934961 0.89 SLC6A11 (0.50) SLC6A11CYP1A2SLC6A1CYP2D6CYP2C9
SCHEMBL3941089 0.88 KDM4E (0.42) S1PR1SMN1; SMN2TSHRCYP2C19HSD17B10
SCHEMBL19897423 0.84 S1PR5 (0.41) S1PR5S1PR4S1PR1S1PR3SLC6A1
SCHEMBL4080259 0.83 NOTUM (0.42) S1PR5S1PR4S1PR1S1PR3SLC6A11
SCHEMBL19289676 0.83 NOTUM (0.42) S1PR5S1PR4S1PR1S1PR3SLC6A11
SCHEMBL262828 0.81 SLC6A1 (0.49) CYP1A2SLC6A1CYP2D6CYP2C9TSHR
SCHEMBL3264345 0.78 CYP1A2 (0.46) S1PR5S1PR4S1PR1S1PR3CYP1A2
SCHEMBL1361559 0.76 S1PR5 (0.43) S1PR5S1PR4S1PR1S1PR3CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220213090-A1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS INCYTE CORPORATION 2022-07-07 — — US claimed
US-20220194931-A1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS INCYTE CORPORATION 2022-06-23 — — US claimed
EP-3558963-A1 BICYCLIC HETEROAROMATIC COMPOUNDS AS IMMUNOMODULATORS Incyte Corporation (US) 2019-10-30 — — EP claimed
EP-3558985-A1 BENZOOXAZOLE DERIVATIVES AS IMMUNOMODULATORS Incyte Corporation (US) 2019-10-30 — — EP claimed
EP-3504198-A1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS Incyte Corporation (US) 2019-07-03 — — EP claimed
US-20180179197-A1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS INCYTE CORPORATION 2018-06-28 — — US claimed
WO-2018119286-A1 BICYCLIC HETEROAROMATIC COMPOUNDS AS IMMUNOMODULATORS INCYTE CORPORATION (US) 2018-06-28 — — WO claimed
WO-2018119266-A1 BENZOOXAZOLE DERIVATIVES AS IMMUNOMODULATORS INCYTE CORPORATION (US) 2018-06-28 — — WO claimed
US-20180179202-A1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS INCYTE CORPORATION 2018-06-28 — — US claimed
WO-2018044783-A1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS INCYTE CORPORATION (US) 2018-03-08 — — WO claimed
US-20180057486-A1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS INCYTE CORPORATION 2018-03-01 — — US claimed
US-11787793-B2 Heterocyclic compounds as immunomodulators INCYTE CORPORATION (US) 2023-10-17 — — US disclosed
US-11613536-B2 Heterocyclic compounds as immunomodulators INCYTE CORPORATION (US) 2023-03-28 — — US disclosed
EP-3504198-B1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS INCYTE CORP (US) 2023-01-25 — — EP disclosed
US-20220213090-A1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS INCYTE CORPORATION 2022-07-07 — — US disclosed
WO-2018119286-A1 BICYCLIC HETEROAROMATIC COMPOUNDS AS IMMUNOMODULATORS INCYTE CORPORATION (US) 2018-06-28 — — WO disclosed
WO-2018119266-A1 BENZOOXAZOLE DERIVATIVES AS IMMUNOMODULATORS INCYTE CORPORATION (US) 2018-06-28 — — WO disclosed
US-20180179202-A1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS INCYTE CORPORATION 2018-06-28 — — US disclosed
WO-2018044783-A1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS INCYTE CORPORATION (US) 2018-03-08 — — WO disclosed
US-20180057486-A1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS INCYTE CORPORATION 2018-03-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220213090-A1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS CD74, IL2, ICOS S1PR5 1112/4885S1PR4 1416/4885S1PR1 792/4885
US-20180179202-A1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS CD74, IL2, ICOS S1PR5 1112/4885S1PR4 1416/4885S1PR1 792/4885
US-20220194931-A1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS CD74, IL2, ICOS S1PR5 1112/4885S1PR4 1416/4885S1PR1 792/4885
US-20180057486-A1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS CD74, IL2, ICOS S1PR5 1112/4885S1PR4 1416/4885S1PR1 792/4885
US-11787793-B2 Heterocyclic compounds as immunomodulators CD74, IL2, ICOS S1PR5 1112/4885S1PR4 1416/4885S1PR1 792/4885
US-11613536-B2 Heterocyclic compounds as immunomodulators CD74, IL2, ICOS S1PR5 1112/4885S1PR4 1416/4885S1PR1 792/4885
US-20180179197-A1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS CD74, IL2, ICOS S1PR5 1112/4885S1PR4 1416/4885S1PR1 792/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.